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ABSTRACT
CONTEXT AND OBJECTIVE: Genetic abnormalities in cell proliferation-regulating genes have been described in premalignant lesions. The aims here were 
to evaluate c-myc protein expression in non-palpable breast lesions associated with microcalcifications, detected by screening mammography, and to 
compare these results with histopathological, clinical and epidemiological variables. 
DESIGN AND SETTING: Analytical cross-sectional study, with retrospective data collection, in a university hospital in São Paulo.
METHODS: Seventy-nine female patients who underwent routine mammography between 1998 and 2004 were studied. Lesions classified by the Breast 
Imaging Reporting and Data System (BI-RADS) as 4 or 5 underwent percutaneous biopsy using a large-core needle. Ninety-eight lesions were studied 
anatomopathologically. Paraffin blocks properly representing the lesions were selected for immunohistochemical analyses using the streptavidin-biotin-
peroxidase technique with monoclonal mouse c-myc antibodies.
RESULTS: Among the 98 lesions, 29 (29.6%) contained malignant neoplasia; 40 (40.8%) had a positive immunohistochemical reaction for c-myc. When 
the groups were divided between lesions without atypias versus atypical lesions plus malignant lesions, 31.03% of the 58 lesions without atypias were 
positive for c-myc and 55% of the 40 malignant and atypical lesions (P = 0.018). Comparing the atypical lesions with ductal carcinoma in situ versus the 
benign lesions without atypias, c-myc was present in 51.61% of the 31 atypical lesions and 31.03% of the benign lesions without atypias (P = 0.057).   
CONCLUSION: C-myc protein was more frequently expressed in atypical and malignant lesions than in benign lesions without atypias. C-myc expression 
correlated with the presence of atypias (P = 0.018).
RESUMO
CONTEXTO E OBJETIVO: Alterações nos genes reguladores da proliferação celular foram descritas em lesões pré-malignas. Os objetivos foram avaliar 
a expressão da proteína c-myc em biópsias de lesões mamárias não-palpáveis associadas a microcalcificações detectadas em mamografias de 
rastreamento e comparar estes resultados com as variáveis histopatológicas, clínicas e epidemiológicas. 
DESENHO E LOCAL: Estudo retrospectivo, em um hospital universitário em São Paulo. 
MÉTODOS: Setenta e nove pacientes do sexo feminino submetidas a mamografia de rotina de 1998 a 2004 foram estudadas. As lesões classificadas pelo 
sistema BI-RADS (Breast Imaging Reporting and Data) como 4 e 5 sofreram biópsias percutâneas com agulha grossa. Do ponto de vista anatomopatológico, 
foram estudadas 98 lesões. Os blocos com representação adequada para estudo imunoistoquímico com a técnica da estreptoavidina-biotina-peroxidase 
com o anticorpo monoclonal de camundongo c-myc foram incluídos. 
RESULTADOS: Das 98 lesões, 29 (29,6%), continham neoplasia maligna; 40 (40,8%) tiveram reação de imunoistoquímica positiva para o c-myc. Quando 
divididos os grupos em lesões sem atipia versus lesões atípicas mais lesões malignas, encontramos o c-myc positivo em 31,03% das 58 lesões sem 
atipias e 55% das 40 lesões atípicas e malignas (P = 0,018). Quando agrupamos as lesões atípicas com o carcinoma ductal in situ (CDIS) versus 
as lesões benignas sem atipias, observamos a presença do c-myc em 51,61% das 31 lesões atípicas e 31,03% das lesões benignas sem atipias 
(P = 0,057). 
CONCLUSÃO: A proteína c-myc está mais frequentemente expressa em lesões atípicas e malignas do que em lesões benignas sem atipia. A expressão 
do c-myc está correlacionada com a presença de atipia (P = 0,018).
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INTRODUCTION
At present, the best screening method for breast cancer is routine 
annual mammography examinations for women over 40 years of age. 
This has been correlated with a reduction of up to 30% in the mortal-
ity rates due to breast cancer, around the world. Screening using mam-
mography is an extremely sensitive method for detecting both malig-
nant and benign breast lesions, and the great majority of breast lesions 
seen on mammographs are non-palpable. The high sensitivity of the 
method is largely due to findings of microcalcifications associated with 
the lesions. Areas of microcalcifications often need to be investigated by 
means of biopsies. Today, 10 to 40% of biopsies on areas of microcalci-
fications find malignant lesions.1-4 Precursor lesions or even minimally 
invasive lesions associated with these microcalcifications provide greater 
accuracy in identifying lesions at early stages. Microcalcifications have 
come to represent 15 to 20% of the breast radiographic abnormalities 
diagnosed in screening tests.5-7 
Today, there are several methodological approaches for perform-
ing breast biopsies. The gold standard is still surgical removal of the 
lesions by means of open surgery.4 However, less invasive methods 
consisting of percutaneous biopsy with a large-core needle, by means 
of both automatic propulsion (core biopsy) and vacuum assistance 
(“mammotomy”), are increasingly used.8 The disadvantage of these 
less invasive types of approach is that they sometimes do not remove 
the lesions, which leads to the need for follow-up regarding the pa-
tient’s remaining microcalcifications.9 
Genetic abnormalities in cell proliferation-regulating genes have 
been described in premalignant lesions.10 Among the oncogenes con-
nected with controlling the cell cycle, the role of the oncogene c-myc 
stands out. Since its discovery by Bishop, in the 1970s, its central role 
in the proliferation and malignant transformation of animal tissue has 
been widely demonstrated.11 
One important carcinogenesis route that has been studied in rela-
tion to breast cancer is the Wnt pathway. The first Wnt gene was cloned 
from the rat genome in 1982. This family produces an enormous quan-
tity of proteins that are related to various normal cell functions, from dif-
ferentiation and proliferation to cell survival capacity.12 The best known 
and most studied are Wnt itself (described in Wilms tumors), adenom-
atous polyposis coli (APC) (responsible for hereditary colon polyposis 
syndrome), catenin (a protein for cell support and connection with the 
basal membrane) and T-cell transcription factor (TCF). There is grow-
ing evidence that the proteins in the Wnt signaling pathway and/or its 
components have an extensive relationship with human breast cancer.13 
Because this is a complex pathway for activating and producing cell 
proteins, it acts in reactions that include several oncogenes. One of the 
target genes that have been described is c-myc.14 For this reason, c-myc 
protein expression is evaluated as an indirect marker for this pathway in 
breast carcinogenesis.
The c-myc protein acts as a transcription factor, i.e. a protein that 
is capable of binding to specific deoxyribonucleic acid (DNA) sites with 
the purpose of modulating the gene transcription. Expression of the 
c-myc gene is unregulated in several types of human neoplasia. Con-
trary to other oncogenes such as those of the ras family, activation of 
c-myc expression does not require mutations or changes in amino acid 
sequences. 
The mechanisms through which the functions of the c-myc gene can 
be altered include action by viral particles; amplification of the locus on 
the chromosome, such as in neuroblastomas (N-myc) and pulmonary 
neoplasia (L-myc); chromosome translocations, such as in Burkitt’s lym-
phomas; or overexpression of the protein due to gene or transcription 
factor mutations. A gene regulation pathway for the c-myc gene through 
the expression line of the Wnt gene has been described. By means of the 
intermembrane receptor, the Wnt gene acts on the protein APC and the 
latter binds to catenin to form a complex in the cytoplasm. When this 
complex is not formed, which could be through changes in the action of 
the Wnt gene, APC or catenin, the latter actively moves to the nucleus 
and acts as a transcription factor for the c-myc gene.14
Under physiological conditions, the main role of c-myc is to pro-
mote cell replication, in response to extracellular signals that arouse the 
cell cycle from rest.15 It is now known that c-myc participates in the ma-
jority of cell functions, for example replication, growth, metabolism, 
differentiation and apoptosis.16-20 Carcinogenesis relating to c-myc oc-
curs when this is expressed aberrantly through amplification or genetic 
alteration, thus leading to events that go from promotion of excessive 
proliferation of altered cells to inhibition of apoptosis.21,22 Amplifica-
tion and/ or overexpression of this gene have been described in almost 
all types of malignant neoplasia in human beings.23 
Amplification of the c-myc oncogene has already been described in 
benign breast lesions such as fibroadenoma.11 We do not know of any 
reports on abnormalities in premalignant lesions associated with micro-
calcifications that were found by means of screening mammography. 
OBJECTIVE
Our objective here was to evaluate the prevalence of c-myc protein ex-
pression in non-palpable breast lesions associated with microcalcifications 
that underwent biopsy following detection by means of screening mam-
mography, and to compare these results with histopathological variables.
MATERIALS AND METHODS
Patients and design
This study was granted prior approval by the Research Ethics Com-
mittee of our university hospital. Ninety-eight lesions among 79 female 
patients who were admitted to our service between 1998 and 2004 were 
studied. All these patients had undergone routine mammography, were 
found to present microcalcifications and were classified as 4 or 5 using 
the 2003 version of Breast Imaging Reporting and Data System (BI-
RADS 2003).24 The patients who were included underwent percutane-
ous biopsies with a large-core needle, using the Mammoguide® system 
(Philips MammoDiagnost MD 4000 mammograph, Philips Medical 
Systems BV, Netherlands) as the guide for image and biopsy site identi-
fication. The techniques used were stereotaxis-guided mammotomy and 
core biopsy with a large-core needle of caliber 12 G, adapted to an auto-
matic propulsion system with a 2.2 cm cursor (Biopty, Bard Urological, 
Covington, Georgia, United States).
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Histological analysis
The samples were fixed in 10% formalin, labeled with the patient’s 
name and sent to the pathology laboratory of the Universidade Federal 
de São Paulo — Escola Paulista de Medicina (Unifesp-EPM). After pro-
cessing and embedding in paraffin, five-micron sections were mount-
ed on slides and stained with hematoxylin and eosin using the recom-
mended technique. 
All the cases included in our study were reviewed from an anato-
mopathological point of view, by two independent pathologists. The 
diagnoses were classified by consensus as benign entities without aty-
pias, premalignant or atypical entities (atypical hyperplasia) or malig-
nant entities.
Immunohistochemical analysis
For the immunohistochemical analysis, new five-micron copies 
from the blocks studied were mounted on blank silanized slides. The 
faithfulness of all the reactions was tested by comparing each of them 
with positive and negative controls that had previously been established, 
which was done concomitantly. All the steps were preceded by two five-
minute baths in phosphate-buffered solution (PBS) at pH 7.4 (except 
for the secondary antibody). 
The c-myc expression was analyzed according to its distribution and 
positivity pattern. It was analyzed in the epithelial component of the tu-
mors. When c-myc protein was found to be present in predominantly 
nuclear locations in more than 10% of the neoplastic cells, this was tak-
en to be a positive finding.
The results obtained were subjected to statistical analysis using de-
scriptive and analytical techniques. The chi-squared univariance test was 
performed (in 2 x 2 tables), and when the frequency was less than five, 
the Fisher test was used. P-values of less than or equal to 0.05 were tak-
en to be significant. 
RESULTS
Among the 98 lesions studied, nine had a diagnosis of invasive 
ductal carcinoma (IDC), 20 were ductal carcinoma in situ (DCIS), 11 
were atypical ductal hyperplasia (ADH) and 58 were benign lesions 
without atypias, such as fibrocystic abnormalities, fibrosclerosis, ade-
nosis and lesions with focal hyperplasia without atypias. 
The c-myc antigen was more frequently expressed in cases of IDC 
and ADH (Table 1). Comparing the atypia cases (ADH) with the be-
nign cases, it was seen that negative findings for c-myc were predom-
inant in the benign cases, and that this was statistically significant 
(P = 0.039; Table 2). The benign cases also seemed to be associated 
with negative c-myc findings when compared with the IDC cases and 
IDC plus DCIS (malignant) cases, although without statistical signifi-
cance (P < 0.061).
Finally, dividing the lesions into two groups, the first containing the 
lesions with atypias and the neoplastic lesions (IDC and DCIS) and the 
second containing the lesions without atypias, the c-myc expression rates 
were 55% and 31.03%, respectively. We observed a greater frequency of 
c-myc in the lesions with atypias, and this difference was statistically sig-
nificant (P = 0.018), as shown in Table 3. 
DISCUSSION
The hypothetical model for tumor progression in breast carcinogen-
esis, through a sequential (multistep) chain of events, was put forward 
by Lakhani in 1999.25 Despite the complexity of studying this model 
for the breast, due to the morphological heterogeneity of preinvasive le-
sions, this author based his theory on three main sources: experiments 
on animals, reviews on human histological material and genetic analyses 
on precursory breast lesions. 
In experiments on animals following exposure to the tumor virus 
MuMTV (murine mammary tumor virus), the normal epithelium was 
found to be transformed into hyperplastic alveolar nodules that, when 
transplanted into normal breast tissue, present a higher chance of malig-
nant transformation. In reviews on human histological material, ADH 
and DCIS were found in specimens of invasive carcinoma, which also 
showed that these lesions occasionally present morphological transition 
and continuity with each other. Furthermore, atypical hyperplasia was 
five times more common in breasts containing malignity than in nor-
mal breasts.25 
Other evidence has come from a review of prospective studies by 
Page et al.26 that found 2.5 times more carcinomas in patients whose 
previous biopsies showed the usual ductal hyperplasia and five times 
Histopathological results n Positive for c-myc %
Invasive ductal carcinoma 9 6 66.7
Ductal carcinoma in situ 20 9 45
Atypical ductal hyperplasia 11 7 66.7
Benign lesions without atypias 58 18 31
Total 98 40 100
Table 1. Expression of the c-myc antigen according to the 
histopathological classification of breast lesions
Types of lesion
c-myc
P
Negative n (%) Positive n (%)
Malignant (IDC and DCIS)
Benign without atypias
14 (48.3)
40 (69.0)
15 (51.7)
18 (31.0)
0.061
Atypias (ADH)
Benign
4 (36.4)
40 (69.0)
7 (63.6)
18 (31.0)
0.039
DCIS
Benign without atypias
11 (55.0)
40 (69.0)
9 (45.0)
18 (31.0)
0.258
IDC
Benign without atypias
3 (33.3)
40 (69.0)
6 (66.7)
18 (31.0)
0.060*
Table 2. Comparison between positive and negative c-myc expression and 
the types of breast lesion, grouped according to benign and malignant 
histological results
IDC = invasive ductal carcinoma; DCIS = ductal carcinoma in situ; ADH = atypical ductal hyperplasia. p-values 
obtained using the chi-squared frequency test. *P-value obtained using the Fisher exact test.
Presence or 
absence of 
atypias
Negative for 
c-myc
%
Positive for 
c-myc
% Total
Without atypias
With atypias
40
18
68.97
45
18
22
31.03
55
58
40
Total 58 40 98
Pearson chi-squared (1) = 5.6286; P = 0.018. 
Table 3. Expression of the c-myc antigen according to the presence or 
absence of cell atypias 
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more when atypical. They found 5.3 times more carcinomas with ADH 
and 11 times more in conjunction with family histories of cancer. These 
authors also showed that in breasts with DCIS in biopsies, 30% more 
invasive carcinomas were found after 6.1 years of follow-up. 
To conclude his theory, Lakhani25 also reported the various progres-
sive genetic similarities between DCIS and IDC, between ADH and 
DCIS and between the usual ductal hyperplasia and atypical ductal hy-
perplasia. In our study, we were also able to observe complexity of pro-
liferative lesions in the same patients. Thus, we found three cases of 
ADH with DCIS and two cases of DCIS with IDC. 
It is known that the carcinogenic process of tumor progression cov-
ers a series of intermediate stages, including activation of oncogenes and 
inactivation of tumor-suppressing genes.27,28 The stages preceding tu-
mor invasion that are described as DCIS and ADH frequently involve 
several early genetic changes.29 These lesions may be found in associa-
tion with infiltrative neoplasia, which suggests that the cumulative pro-
cedure of genetic damage does not always follow a single linear sequence 
of events.30 
The activated c-myc gene may perform an important biological role 
in the tumorigenesis process.31 One of the most important actions in-
volves the proliferation process. Early induction of c-myc may occur 
through different pathways, involving the transition from the quiescent 
cellular state (G0) to proliferation (G1). Moreover, c-myc is continually 
expressed in cells undergoing proliferation.31 The mechanism for action 
leading to the entry of cells into the cell cycle involves inactivation of 
cyclin-kinase antagonist proteins and inactivation of the cyclin E antag-
onist. The presence of c-myc from G1 onwards seems to be essential for 
the cell cycle sequence.32 On the other hand, in cells that enter the dif-
ferentiation process, the expression decreases and this is important for 
terminal differentiation. Since c-myc expression is also associated with 
the apoptosis process, lack of control over c-myc expression may lead to 
increased cell death.31 
In a meta-analysis, Deming et al.33 observed that, on average, 15.5% 
of breast cancer biopsies presented c-myc gene amplifications of more 
than three times normal values. Studies using the immunohistochemi-
cal technique have demonstrated that, in 50 to 100% of the cases, there 
were increased levels of the c-myc protein.34 Mai showed that there was 
a greater percentage of cancer cases with aberrant c-myc protein levels 
than of cases showing gene amplification. This would also imply that 
changes in the stability of messenger ribonucleic acid (RNA) or its pro-
tein could be the mechanism for increased c-myc levels, which would be 
consistent with reports that overexpression precedes gene amplification, 
thereby leading to chromosome instability.35 
Following this line of reasoning, it might be supposed that findings 
of c-myc protein in benign lesions, as in our study, could precisely repre-
sent this initial step of gene overexpression and/or amplification and the 
initial step in breast carcinogenesis. In fact, when we compared the pres-
ence of c-myc in atypical lesions with its presence in benign lesions with-
out atypias, we found a statistically significant difference (P = 0.039). 
Likewise, dividing the lesions into two groups, such that the first con-
tained the lesions with atypias and the neoplastic lesions (IDC and 
DCIS) and the second contained the lesions without atypias, the c-myc 
expression was 55% and 31.03%, respectively. Thus, we observed great-
er frequency of c-myc in the lesions containing atypias, and this differ-
ence was also statistically significant (P = 0.018). 
Even without reaching significance, we could see a certain tendency 
(P = 0.06) towards c-myc expression when the IDC and DCIS results 
and the results from the benign lesions were analyzed together. This was 
also seen when we compared the IDC findings alone with the benign le-
sions (P = 0.06). These results allow it to be presupposed that the pres-
ence of c-myc may signify increased risk of progression of the benign 
proliferative lesions, or even of the DCIS. 
The number of cases studied did not allow separate identification of 
the individual pattern of c-myc expression in the benign breast lesions, 
separated according to the relative risk of progressing to invasive carci-
noma. Nevertheless, among the adenosis, papilloma and typical ductal 
hyperplasia cases (lesions that are said to be proliferative and consid-
ered to present a low risk of breast cancer), we found six cases that were 
positive for c-myc, out of the 14 studied. On the other hand, among 
the non-proliferative lesions, such as fibrocystic abnormalities, only one 
case out of 14 was positive. 
We also observed that the pattern of c-myc presence was variable 
and that it could coexist in different lesions in the same patient. For 
example, in some patients in whom malignant lesions and low-risk be-
nign proliferative lesions (such as adenosis and the usual ductal hyper-
plasia) coexisted, we found that both types of lesion were positive for 
c-myc (two cases out of six evaluated). This finding reinforces the sup-
position that the initial lesion (adenosis) had already been amplified by 
the c-myc gene much before the evolution into an atypical proliferative 
lesion or even into carcinoma. It corroborates the hypothetical model 
for tumor progression through a multistep sequential chain of events for 
breast carcinogenesis.25
Schmitt and Reis-Filho36 reported positive findings of c-myc in 
breast cancer cases, ranging from 1% to 94.4%. This large difference 
in positive findings of c-myc has a variety of reasons. Among these, per-
haps the main reason is differences in investigation methods, which may 
make use of immunohistochemical or hybridization techniques, such as 
fluorescence in situ hybridization (FISH) and chromogenic in situ hy-
bridization (CISH). These latter methods are clearly more sensitive, but 
much more expensive to perform. 
Another reason would be the fact that c-myc presence is related to 
different types of tumor. For example, high nuclear grade tumors have 
a higher chance of presenting overexpressed proteins than do low grade 
tumors.11 
Reinforcing this idea of overexpression of c-myc protein in cells that 
are more differentiated, Le Roy et al.37 demonstrated that patients with 
breast tumor receptors positive for estrogens who received treatment 
with tamoxifen showed decreased levels of c-myc messenger RNA, in 
comparison with patients who had not received this drug. This result 
suggests that tamoxifen antagonized the effect of estrogens in relation 
to c-myc expression. 
It is known that percutaneous biopsies from benign lesions such 
as typical ductal hyperplasia, florid adenosis, papillomatosis and even 
atypical ductal hyperplasia result in some cases of underestimated diag-
nosis. It is also known that, during follow-up, some of these lesions end 
up evolving into carcinoma. We might therefore suggest that tamoxifen 
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should be used in cases of biopsy findings of benign proliferative lesions 
that nonetheless are positive for c-myc.
The study by Berns et al.38 also suggested that there is an inverse re-
lationship between c-myc presence and human epidermal growth factor 
receptor 2 (HER2/neu) presence. This opens up even greater possibili-
ties for future studies on c-myc involving possible drug preparations that 
would be capable of acting directly on amplified c-myc, in the same way 
as with c-erb-b2, such as the use of herceptin and HER2/neu.
Studying the expression of the c-myc gene has produced some guide-
lines regarding carcinomas that may in the future contribute towards 
more accurately determining tumor behavior, because of the associa-
tions of c-myc with cell proliferation and chemoresistance.39 
CONCLUSION
The c-myc protein is more frequently expressed in atypical and ma-
lignant lesions than in benign lesions without atypias. The expression of 
c-myc correlates with the presence of atypias. 
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